Home Ingredients Senna
Gut Health

Senna

Senna alexandrina (Cassia angustifolia)
Evidence Level
Strong
2 Clinical Trials
4 Documented Benefits
4/5 Evidence Score

Senna is a stimulant laxative derived from the dried leaves and pods of Senna alexandrina (Cassia angustifolia). Its laxative effect comes from anthraquinone glycosides called sennosides, principally sennosides A and B, which are hydrolyzed by colonic bacteria into active rhein anthrones that stimulate peristalsis and alter water and electrolyte transport in the large intestine. In the United States senna laxatives are sold as over-the-counter drugs with a Drug Facts label rather than as dietary supplements, and senna is well established for short-term relief of occasional constipation. It is also used in palliative care and opioid-induced constipation protocols, but that use belongs under clinical supervision. It is important to use senna only as needed and for the shortest necessary time, as chronic daily use carries documented risks including cathartic colon, melanosis coli and electrolyte disturbances, and it is not a daily fiber supplement.

Studied Dose 15-30 mg sennosides/day for short-term use only. Over-the-counter labeling directs users not to take a laxative product for longer than 1 week unless a doctor says otherwise.
Active Compound Anthraquinone glycosides, principally sennosides A and B, hydrolyzed by colonic bacteria into active rhein anthrones.

Benefits

Short-Term Constipation Relief

Senna is a well-established stimulant laxative for short-term relief of occasional constipation. Over-the-counter labeling states that a dose generally produces a bowel movement in 6 to 12 hours, which is why it is usually taken at bedtime. In a 28-day double-blind placebo-controlled trial in 90 adults with long-standing constipation, 93% of them women, symptoms improved in 69.2% of the senna group versus 11.7% on placebo.

Supported by Trial 2

Pre-Procedure Bowel Preparation

Senna-based preparations are used in some bowel-cleansing protocols before colonoscopy and other procedures, where reliable, complete evacuation of stool is essential. A meta-analysis of 11 trials in 3,343 patients found senna regimens gave bowel cleanliness no different from other preparations, but with better patient compliance and less nausea. This is a supervised hospital procedure carried out to a doctor's written instructions, not something to attempt on your own.

Supported by Trial 1, Trial 2

Opioid-Induced Constipation Support

Senna is a common first-choice stimulant laxative for opioid-induced constipation in palliative care, where opioid analgesics predictably slow intestinal transit. The evidence here comes from seriously ill patients: in a randomized trial in 91 terminal cancer patients on opioids, senna and lactulose relieved constipation about equally well, and senna cost less. A result obtained in that population does not automatically transfer to a healthy reader. Use is typically combined with stool softeners under clinical supervision.

Supported by Trial 1, Trial 2

Predictable Onset of Action

Senna's reliable 6-12 hour onset, taken at bedtime, makes it convenient for occasional use when a predictable next-morning result is needed. It is not appropriate as a daily maintenance product for chronic constipation.

Supported by Trial 2, Trial 1

Mechanism of action

1

Sennoside Activation in the Colon

Senna's sennoside glycosides pass intact through the small intestine and are hydrolyzed by colonic bacterial enzymes to active rhein anthrones in the large intestine. This localizes the laxative effect to the colon and explains the characteristic 6-12 hour onset.

2

Stimulation of Colonic Peristalsis

Rhein anthrones act on the myenteric plexus and on colonic smooth muscle, increasing the frequency and amplitude of propulsive contractions. The result is faster transit of fecal material through the colon.

3

Alteration of Water and Electrolyte Transport

Senna metabolites inhibit colonic Na+/K+-ATPase and modulate aquaporin-mediated water transport, reducing fluid absorption and slightly increasing colonic secretion. This softens stool and supports the propulsive effect.

Clinical trials

1
Cochrane Review of Laxatives in Palliative Care

Cochrane systematic review of randomized controlled trials evaluating laxatives, including senna, lactulose and combinations, for the management of constipation in palliative care patients.

5 included RCTs involving palliative-care patients with constipation. Each of the five trials compared different laxatives against each other, so no pooled analysis was possible.

Senna and other commonly used laxatives showed broadly similar effectiveness for constipation in palliative care, with evidence limited by small sample sizes and heterogeneous outcomes. The review's own stated conclusion was that there was no evidence on whether any individual laxative, senna included, was more effective than another or caused fewer adverse effects. It also warned that findings on laxatives from other populations should not be extrapolated to palliative care. So this review does not show senna beating anything, and it is specifically about people receiving palliative care.

2
Sodium Picosulfate, a Different Laxative, vs Placebo for Chronic Constipation

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in 367 adults with chronic constipation. Sodium picosulfate is not senna and is not even the same chemical family: senna works through anthraquinones, picosulfate through a diphenylmethane compound, though both are switched on by colonic bacteria. Primary outcome was complete spontaneous bowel movements per week.

367 adults with chronic constipation defined by Rome III criteria.

The active stimulant laxative increased complete spontaneous bowel movements from 0.9 to 3.4 per week versus 1.1 to 1.7 for placebo, and improved quality-of-life measures. Treatment was generally well tolerated; the trial supports the general idea that a colon-activated stimulant laxative works, but because it tested a different drug it is not evidence for senna itself and should not be read as such.

Side effects and drug interactions

Common Potential side effects

Abdominal cramping, gas and bloating, especially at higher doses.
Diarrhea and urgency if dose is excessive or repeated.
Chronic daily use can cause cathartic colon with reduced colonic motility.
Long-term use is associated with melanosis coli, a benign brown pigmentation of the colonic mucosa.
Prolonged use can cause electrolyte imbalance, particularly hypokalemia. Liver injury has also been reported when senna is taken in high doses for longer than recommended, including a documented case of acute liver failure with kidney impairment after years of heavy senna use. In practice the people most at risk are those taking senna daily in weight-loss or detox tea products, which is exactly the pattern of use this ingredient should never be put to.

Important Drug interactions

Prolonged use can cause hypokalemia, potentiating digoxin toxicity.
Hypokalemia can interact with antiarrhythmic drugs and increase arrhythmia risk.
May reduce absorption of oral medications by accelerating intestinal transit.
Combining with diuretics worsens potassium loss and electrolyte disturbances.

More Gut Health Ingredients

Gut Health
Pancrelipase / Pancreatin
Pancrelipase (also called pancreatin) is a standardized blend of three primary pancreatic…
Gut Health
Sunfiber® (Partially Hydrolyzed Guar Gum)
Sunfiber® is the original and most extensively clinically-studied partially hydrolyzed gua…
Gut Health
Peppermint (Mentha × piperita)
Peppermint is a hybrid mint (Mentha aquatica × Mentha spicata) whose leaves and extracted…
Gut Health
PepZinGI® (Zinc-Carnosine for Gut Lining)
PepZinGI® (NutriScience Innovations) is a unique chelate of zinc and L-carnosine in a 1:1…

Related articles from our blog

📝 Article
Do Detox and Cleanse Supplements Work?
Every January, and most of the months in between, the internet fills up with detoxes and cleanses: green juices, "liver…

Frequently asked questions about Senna

What is senna used for?

Senna is an herbal stimulant laxative used for short-term relief of occasional constipation. Its compounds (sennosides) stimulate the bowel to contract, producing a bowel movement, usually within 6 to 12 hours.

How does senna work, and when?

Senna stimulates the intestinal muscles to move stool along, typically working within 6 to 12 hours, so it is often taken at bedtime for a morning result. It is for short-term, occasional use, not daily long-term use.

How much senna should I take?

Follow product labeling for the standardized sennoside content, using the lowest effective amount. Take it with plenty of water, and do not exceed the recommended duration (usually about a week).

Is senna safe?

For occasional short-term use it is generally safe. However, regular long-term use of stimulant laxatives can lead to dependence, electrolyte problems and, rarely, liver injury, so it should not be used daily for extended periods. Daily use in weight-loss or detox teas is the main way people run into trouble with senna. Pregnant women and those with bowel conditions should check with a doctor.

What is Senna?

Senna is a stimulant laxative derived from the dried leaves and pods of Senna alexandrina (Cassia angustifolia). Its laxative effect comes from anthraquinone glycosides called sennosides, principally sennosides A and B, which are hydrolyzed by colonic bacteria into active rhein anthrones that stimulate peristalsis and…

What is the recommended dosage of Senna?

The clinically studied dose is 15-30 mg sennosides/day for short-term use only. Over-the-counter labeling directs users not to take a laxative product for longer than 1 week unless a doctor says otherwise. Always follow the product label and check with a healthcare provider for personal advice.

Is Senna safe, and does it have side effects?

For most healthy adults, Senna is well tolerated at studied doses. Reported effects can include: Abdominal cramping, gas and bloating, especially at higher doses. Diarrhea and urgency if dose is excessive or repeated. It may also interact with some medications. Senna is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Senna interact with any medications?

Possible interactions include: Prolonged use can cause hypokalemia, potentiating digoxin toxicity. Hypokalemia can interact with antiarrhythmic drugs and increase arrhythmia risk. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Senna?

NutraSmarts rates the evidence for Senna as Strong (4 out of 5). It is backed by 2 clinical trials and 8 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(8 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database Syst Rev. 2015;(5):CD003448. doi: 10.1002/14651858.CD003448.pub4.PubMedUsed to support: Cochrane systematic review of laxatives (including senna) for constipation in palliative care, Its stated conclusion was that there was no evidence on whether individual laxatives were more effective than others or caused fewer adverse effects, and it cautioned against extrapolating laxative findings from other populations. It documents that senna is used and is not worse than the alternatives in palliative care; it does not establish that senna works.
  2. Mueller-Lissner S, Kamm MA, Wald A, Hinkel U, Koehler U, Richter E, Bubeck J. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010;105(4):897-903. doi: 10.1038/ajg.2010.41.PubMedUsed to support: Important limitation stated up front: this trial tested sodium picosulfate, not senna. It was a randomized placebo-controlled trial in 367 adults with chronic constipation showing significant increases in complete spontaneous bowel movements, so it supports stimulant laxatives as an approach but contains no senna-specific evidence.
  3. Rao SSC, Brenner DM Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review. Am J Gastroenterol. 2021;116(6):1156-1181..PubMedUsed to support: Systematic review of 41 randomized trials of at least 4 weeks duration, scored by US Preventive Services Task Force criteria. Found good evidence, grade A recommendation, for polyethylene glycol and for the stimulant senna, and concluded that polyethylene glycol or senna are the first-line laxative choices. Honest limits: the work received support from Bayer US LLC, which markets a competing polyethylene glycol product and does not market senna, so the senna grade is not a sponsor-favouring result; the authors also note variable study design, differing primary outcomes and small sample sizes across the literature. This is the strongest single citation for the page's core efficacy claim.
  4. Morishita D, Tomita T, Mori S, et al. Senna Versus Magnesium Oxide for the Treatment of Chronic Constipation: A Randomized, Placebo-Controlled Trial. Am J Gastroenterol. 2021;116(1):152-161..PubMedUsed to support: The senna-specific placebo-controlled trial the page was missing. Double-blind randomized trial in 90 adults with chronic idiopathic constipation (mean age 42, 93% women, mean symptom duration 9.9 years) given senna 1.0 g, magnesium oxide 1.5 g, or placebo daily for 28 days. Overall improvement was 69.2% on senna versus 11.7% on placebo (P less than 0.0001), with significantly greater increases in spontaneous and complete spontaneous bowel movements and better constipation quality-of-life scores. No severe treatment-related adverse events. Honest limits: a single trial with roughly 30 people per arm, almost all women, and senna dosed as 1.0 g of the crude drug rather than as a stated milligram amount of sennosides. Backs benefit 1, short-term constipation relief.
  5. Agra Y, Sacristán A, González M, et al. Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. J Pain Symptom Manage. 1998;15(1):1-7..PubMedUsed to support: Randomized, open, parallel-group trial in 91 terminal cancer patients on opioids in a Madrid palliative care unit, comparing senna with lactulose over 27 days. No difference between the two in defecation-free intervals of 72 hours, days with defecation, or general health status, and the authors recommended senna because it costs less. Honest limits: open-label, an active comparator with no placebo arm, and the population is terminally ill cancer patients under clinical supervision rather than general readers. Backs benefit 3, opioid-induced constipation, with an actual senna trial instead of the Cochrane review, which explicitly declines to rank laxatives.
  6. Tian H, Fan Y, Yang L, et al. The Efficacy of Senna Bowel Preparation for Colonoscopy: A Systematic Review and Meta-analysis. Gastroenterol Nurs. 2022;45(6):428-439..PubMedUsed to support: Systematic review and meta-analysis of 11 trials in 3,343 patients. Bowel cleanliness with senna regimens was not significantly different from other preparations (odds ratio 1.02, 95% CI 0.63 to 1.67, P=0.93), while senna showed better patient compliance (odds ratio 3.05, 95% CI 1.42 to 6.55, P=0.004), better tolerance (odds ratio 1.66, 95% CI 1.08 to 2.54, P=0.02) and a significantly greater proportion of patients with no nausea (odds ratio 1.84, 95% CI 1.45 to 2.32). The vomiting result favoured senna but was not statistically significant (odds ratio 1.65, 95% CI 0.81 to 3.35). Backs benefit 2, pre-procedure bowel preparation, while making clear the advantage is tolerability rather than better cleaning and that this is a supervised clinical use.
  7. National Institute of Diabetes and Digestive and Kidney Diseases Senna. LiverTox, National Institute of Diabetes and Digestive and Kidney Diseases. 2020;Bethesda (MD), chapter updated 1 April 2020..PubMedUsed to support: States that senna is generally safe and well tolerated but can cause adverse events including clinically apparent liver injury when used in high doses for longer than recommended periods, attributes the injury to the anthraquinone derivatives, notes that most cases involved excessive doses, that injury is usually self-limited and reversible on stopping, that severe courses with signs of acute liver failure have been described, and that restarting senna after liver injury has been associated with recurrence and should be avoided. Supports the liver-injury line added to the safety section and the page's insistence on short-term use only.
  8. Vanderperren B, Rizzo M, Angenot L, et al. Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. Ann Pharmacother. 2005;39(7-8):1353-7..PubMedUsed to support: Case report of a 52-year-old woman who drank about one litre of senna tea daily, prepared from roughly 70 g of dry senna fruits, for more than three years and developed acute liver failure together with proximal tubular acidosis; she recovered with supportive care and did not require transplantation. Honest limits: a single case at an extreme dose far above labelled use, so it marks the ceiling of chronic misuse rather than any risk of occasional labelled use. Cited for the specific acute liver failure case named in the safety section and for the real-world weight-loss and detox tea misuse pattern.